Novozymes completed the acquisition of PrecisionBiotics Group for $90m.

Novozymes, a global biotechnology company, completed the acquisition of PrecisionBiotics Group, a provider of probiotics for human gut health, for $90m. “By becoming a part of Novozymes, we will get a global presence across businesses and new capabilities within science and discovery of new strains. This will help us to grow by developing new products where we can combine enzymes and probiotics,” Barry Kiely, PrecisionBiotics CEO and Co-Founder.